Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy), P. Rogliani (Rome, Italy), C. Page (London, United Kingdom), M. Matera (Naples, Italy). Impact of doxofylline in COPD: a pair-wise meta-analysis. 616

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety profile of xanthines in COPD: a network meta-analysis Source: Eur Respir Rev, 27 (148) 180010; 10.1183/16000617.0010-2018 Year: 2018 Efficacy and safety profile of xanthines in COPD: a network meta-analysis Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Prevalence of COPD: updated meta-analysis results Source: Annual Congress 2007 - Environmental and clinical aspects of COPD Year: 2007 Job strain and COPD exacerbations: an individual-participant meta-analysis Source: Eur Respir J 2014; 44: 247-251 Year: 2014 Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Risk of pneumonia related to budesonide use in COPD: An updated pooled analysis Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Combined tiotropium + olodaterol influences physical functioning in COPD: Results of an open-label observational study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy of psychosocial intervention in COPD: a systematic review and meta-analysis Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015